On further investigation, it seems that the company will have one month to respond to the outstanding issues if these are adopted at the meeting. That means the earliest meeting for approval would be November. If not at that one then December.
Can anyone else confirm this?
I notice that there is another application that is going through the same hoops (i.e., EMEA/H/D/003740: human serum albumin).
